Pharmacia parecoxib
Executive Summary
Pharmacia will submit additional data to FDA in 12 to 18 months following July 13 "not approvable" letter for its injectable COX-2 inhibitor parecoxib. The letter "indicated that there were deficiencies in the application," and requested confirmatory data, Pharmacia said. The application was filed in September 2000
You may also be interested in...
Pfizer Elaborates On Celebrex Safety Theory: Molecule Is “Unique”
Celebrex can be differentiated from other COX-2 inhibitors based on relative rates of association with hypertensive cell retention, Pfizer Worldwide Development President Joe Feczko told analysts Nov. 30 in Groton, Conn
Pfizer Elaborates On Celebrex Safety Theory: Molecule Is “Unique”
Celebrex can be differentiated from other COX-2 inhibitors based on relative rates of association with hypertensive cell retention, Pfizer Worldwide Development President Joe Feczko told analysts Nov. 30 in Groton, Conn
Pharmacia Bextra Pre-Launch Will Develop “Real Life Experience” With Drug
Pharmacia will pre-launch Bextra with select physicians to gather "real life experience" in advance of the COX-2 inhibitor's full launch in April